Total Funding
69
65
Total FundingSeed raised
Growth Score
-14 pts
Heat Score
-11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
62828
Game-changing therapeutic nanoparticles for neuroscience, chronic degenerative diseases and orthopaedics.
- Stephan Crokaert: Chief Operating OfficerPast Role: NeoMedLight, Global Director of Marketing and Business Development
- Lucas Decuypere: PresidentPast Role: iO, Managing Director and Partner
About the Company
Allegro was founded in 2021 with the ultimate vision to augment humanity and prolong life, engineering the body atom-by-atom, blending nanotech and biotech. The company developed a promising nanotechnology platform to build therapeutic nanoparticles for orthopaedics, neuroscience, and chronic degenerative diseases. Allegro brings Xyletra to the
market, the world's first disease-modifying treatment for osteoarthritis, which stops the degenerative process and alleviates pain with a year-long effect on a single shot administration.
